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Influence of nycthemeral blood pressure pattern in treated hyperten-
sive patients on hemodialysis. Arterial hypertension in end-stage renal
disease (ESRD) patients is characterized by an altered nycthemeral blood
pressure (BP) rhythm and an increased pulse pressure, and it could be
suggested that this association of risk factors plays a major role in the
cardiovascular prognosis of this population. The aim of this study was to
determine the influence of nycthemeral BP pattern on arterial distensi-
bility and pulsatile components of BP in treated hypertensive patients on
regular hemodialysis. Forty-two hypertensive patients were included, and
all underwent ambulatory BP and pulse wave velocity (PWV) measure-
ments between the femoral and carotid arteries. The patients were divided
into two groups according to the magnitude of the nocturnal fall in BP:
dippers and non-dippers. The groups were similar in gender, age, duration
of hemodialysis, body mass index, body size, history of cardiovascular
complications, class and number of antihypertensive drugs used per
patient. PWV was significantly higher in non-dippers. For the whole
population, a stepwise regression analysis showed that PWV and erythro-
poietin therapy were independently related to the impaired nycthemeral
BP pattern. In addition to its pressor effect, erythropoietin could have a
deleterious influence on the ambulatory BP profile of treated hypertensive
patients in ESRD. Arterial distensibility and nycthemeral BP impairment
are linked, and these cardiovascular risk factors should be taken into
account together for the management of hypertensive hemodialysis pa-
tients.
Cardiovascular diseases are the main cause of morbidity and
mortality in hemodialysis patients. Despite the appearance of new
antihypertensive drugs, hypertension remains the main cardiovas-
cular risk factor in this population. Arterial hypertension in
end-stage renal disease (ESRD) patients is characterized by an
altered nycthemeral blood pressure pattern [1] and an increased
pulse pressure [21. Blood pressure (BP) can be divided into two
components: a steady component (mean arterial pressure) and a
pulsatile component (pulse pressure). The pulse pressure repre-
sents the oscillation around this mean and is determined by left
ventricular ejection and arterial stiffness [3]. The increase in pulse
pressure in hemodialysis patients has been attributed to arterial
distensibility impairment [2]. Blood pressure is a periodic phe-
nomenon with a circadian pattern characterized by a nocturnal
decrease. The lack of fall in nocturnal BP could be related to an
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increased activity of the sympathetic nervous system in hemodi-
alysis patients [4]. Since the prognostic value of increased pulse
pressure [5] and impaired circadian BP pattern [6] has been well
established, it is suggested that this association of risk factors,
which characterize arterial hypertension in ESRD patients, plays
a major role in the cardiovascular prognosis of this population.
Whether the arterial stiffness and the lack of fall in nocturnal BP
are linked or not remains to be confirmed. The purpose of this
study is to determine the influence of nycthemeral BP pattern on
arterial distensibility and pulsatile components of BP in treated
hypertensive hemodialysis patients.
Methods
Subjects
All the 46 hypertensive hemodialysis patients of our unit were
screened. We excluded patients with evidence of autonomic
dysfunction, particularly orthostatic hypotension, patients who
were not able to support ambulatory BP monitoring, and patients
receiving antihypertensive therapy for less than six months. Forty-
two of 46 patients finally enter the study. The duration of dialysis
therapy was 76.32 65 months (range 12 to 228 months). The
patients were dialyzed three times per week. The duration of
dialysis was individually adjusted to control body fluids and blood
chemistry. The dialysate was delivered by a system comprising
bicarbonate delivery and ultrafiltration devices. An arteriovenous
shunt was used in all patients. Seven were diabetics; 13 of 42
(3 1%) had a past history of cardiovascular events; 31 of 42 (74%)
received erythropoietin. The quality of hemodialysis therapy was
assessed by the Kt/V index calculation [7] during the month
before the ambulatory blood pressure measurement.
Blood pressure measurements
Casual BP. BP was measured with a mercury sphygmomanom-
eter with cuffs adapted to arm circumference in the seated
position according to the recommendations of the British Hyper-
tension Society [8].
Ambulatory BP measurements. An ambulatory BP measurement
(ABPM; SPACELABS 90207 monitor; Redmond, WA, USA) was
performed between two dialysis sessions. BP was measured every
15 minutes during the daytime period (6 am. to 10 p.m.), and
every 30 minutes during the nocturnal period (10 p.m. to 6 a.m.).
Our study group was divided into two groups according to the
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Table 1. Clinical and hemodynamic characteristics of dippers and non-
dippers
Dippers(N=18) Non-dippers(N=24) P
Age years
Sex rn/f
Body size rn
BMI kg/rn2
Duration of HD years
Kt/V
Interdialytic weight gain kg
Interdialytic weight variation %
Past history of
CV complications %
Diabetes mellitus %
Parathyroidectomy %
LVMI g/rn
LVH %
Erythropoietin therapy %
56.2 16.7
13/5
1.67 0.1
23.7 5.2
7.77 6.22
1.264 0.204
2.21 0.69
3.47 1.33
5 (27.78%)
1(5.55%)
5 (27.77%)
151.3 27.5
13 (76.47%)
10 (55.55%)
62 11.5
15/9
1.64 0.9
22 2.46
5.37 4.55
1.34 0.145
2.042 1.19
3.47 1.19
7 (29.17%)
5 (20.8%)
2 (8.33%)
149.1 52.7
14 (66.67%)
21(87.5%)
0.19
0.74
0.47
0.18
0.15
0.13
0.44
0.98
0.8
0.33
0.2
0.87
0.5
0.04
Casual BPmm Hg
systolic BP
diastolic BP
pulse P
mean arterial P
141.22 17.09
82.61 8.2
58.61 13.91
102.14 9.96
144.41 21.41
84.69 11.36
60.21 14.28
104.76 14.09
0.6
0.5
0.71
0.5
Ambulatory BPmm Hg
day time
systolic
diastolic
night time
systolic
diastolic
139.72 18.17
82.05 10.38
124.94 13.75
71.77 8.42
138.25 16.39
80.62 9.97
147.29 21.66
84.08 11.82
0.78
0.65
0.0004
0.0006
Pulse wave velocity rn/second 11.47 3.44 14.09 4.08 0.03
Abbreviations are: LVMI, left ventricular mass index; LVH, left ven-
tricular hypertrophy; BP, blood pressure; CV, cardiovascular; BMI, body
mass index.
magnitude of the nocturnal fall of BP. Non-dippers were arbi-
trarily defined by an absence of nocturnal dip or an inversion of
circadian pattern; the remaining subjects were classified as dip-
pers.
In twelve patients ABPM was performed twice, on different
interdialytic days, and the classification between dippers and
non-dippers remained unchanged.
Arterial distensibility
Arterial distensibility was estimated by pulse wave velocity
(PWV) measurement [9—11]. PWV is a classic index of arterial
stiffness. It was measured by means of 2 pulse transducer heads
between the common carotid artery and the right femoral artery.
The femoral and the carotid pulses were recorded simultaneously
with a paper speed of 200 mm/second (8188 Gould recorder;
Gould Electronique, Ballainvilliers, France). The distance trav-
elled by the pulse wave was measured over the corporeal surface
with a tape measure as the distance between the two recording
sites. The distance from the suprasternal notch to the carotid was
subtracted from the total distance to take into account the pulse
traveling in the opposite direction. The foot-to-foot arterial wave
velocity was calculated as the ratio between this distance and the
time interval separating the feet of carotid and femoral waves.
Table 2. Biological characteristics of dippers and non-dippers
Dippers(N=18) Non-dippers(N=24) P
Hemoglobin g/dl 10.21 1.19 9.97 1.18 0.53
Calcemia mmol/l 2.25 0.15 2.37 0.26 0.09
Phosphoremia rnrnol/liter 1.62 0.5 1.98 0.91 0.15
Parathormon pg/ml 135.72 42.32 172.04 52.74 0.02
Echocardiographic measurements
Two-dimensionally guided M-mode echocardiography was per-
formed with an HP Sonos 100 (Hewlett-Packard Co., Evry,
France) using a 3.5 MHz transducer. Left ventricular dimensions
were measured by two readers according to the recommendations
of the American Society of Echocardiography [12]. Left ventric-
ular mass (LVM) was calculated according to the Penn conven-
tion. Left ventricular mass index (LVMI) was determined by
dividing LVM by body height (LVMI in grams per meter).
Blood chemistry
Blood samples were drawn after a 12-hour fast, from the
dialysis access, just before the start of hemodialysis. Phosphore-
mia, calcemia and alkaline phosphatase level were assayed by
autoanalyzer (RA 1000; Technicon, Dumont, France) and serum
intact parathyroid hormone (PTH) by radio immunoassay (Sorin
Biomedica, Antony, France).
Results
Study population
Tables 1 and 2 show the characteristics of dippers (D) (18 of 42)
and non-dippers (ND) (24 of 42). The two groups were not
significantly different regarding age, sex, duration and quality of
hemodialysis, mean interdialytic weight gain, body mass index,
body size, past history of cardiovascular complications, classes and
number of antihypertensives, and LVMI (Table 3). To take into
account the influence of the pharmacokinetic properties of the
antihypertensive drugs on the nycthemeral BP pattern, we indi-
vidualized the group analysis according to the current prescribing
information: long acting drugs that can be given once daily, and
short acting drugs that must be given at least twice daily to be
efficient for a whole day. Neither the class of the drugs nor the
rhythm of administration were significantly different between
dippers and non-dippers. In dippers, 14 patients (77.7%) took
long acting drugs and 8 patients (44.4%) took their antihyperten-
sive treatment twice daily (morning and night). In non-dippers 19
(79.1%) patients took long acting drugs (P = 0.78) and 14
(58.83%) took their antihypertensive drugs twice daily (P =0.54).
Based on Penn convention measurements, left ventricular hyper-
trophy (LVH) was defined as LVMI greater than 143 glm for men
and 102 g/m for women. Using these cutoff points, no difference in
the prevalence of LVH has been found between the two groups.
The prevalence of diabetes tended to be higher in non-dippers.
As usually described, PWV was positively related with age and
casual systolic BP. In addition, we found a positive relationship
between PWV and 24-hour systolic ambulatory BP. Diurnal,
nocturnal and 24-hour heart rate variability were not significantly
correlated with PWV (Table 4). PWV was not significantly
correlated with intact PTH, calcemia, phosphoremia and hemo-
globin levels. PWV is higher in patients with past history of
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Table 3. Number and classes of antihypertensives used in our study
group
Dippers(N=18) Non-dippers(N=24) P
Number of antihypertensives 1.33 0.48 1.5 0.72 0.4
ACE inhibitors % 9 (50) 12 (50) 1.00
Calcium antagonists % 11(61.1) 19 (79.1) 0.34
Beta blockers % 4 (22.2) 2 (8.3) 0.4
CAD % 0(0) 3 (12.5) 0.34
Abbreviations are: ACE, angiotensin converting enzyme; CAD, central
acting drugs.
cardiovascular complications than in patients free from a previous
history of myocardial infarction or stroke (15.58 5.12 vs.
12.04 3.27 m/second; P = 0.01).
Chemical parameters
Calcemia tended to be increased in ND. Intact PTH level was
significantly higher in ND. Hemoglobin level was not significantly
different between the two groups, but more patients received
erythropoietin in the ND group (10 of 18 vs. 21 of 24; P =0.01).
Among the patients receiving erythropoietin (EPO), the mean
EPO dose used was not significantly different between dippers and
non-dippers (82.4 54.87 vs. 109 62.08 UI/kg/week, respec-
tively; P = 0.25). On the other hand, the prevalence of non-
dippers was higher in patients on EPO therapy (21 of 31; 67.74%)
than in patients not receiving EPO (3 of 11; 27.27%; P =0.04).
Hemodynamic parameters
No significant difference between the two groups was found in
casual systolic, diastolic, mean and pulse pressure, diurnal systolic
and diastolic ambulatory BP. Pulse wave velocity was significantly
higher in non-dippers. When the diabetic patients were excluded,
PWV tended to stay higher in non-dippers, but the difference was
no more significant (PWV m/second 11.5 3.5 vs. 13.8 4.3; P =
0.09). However, in this subgroup PWV remained correlated with
casual systolic BP and 24-hour systolic ambulatory BP. For the
whole population, in stepwise regression analysis, PWV and
eiythropoietin therapy appeared to be independently related to
the lack or inversed nycthemeral BP pattern. When PWV was
removed from the analysis, pulse pressure (PP) introduced in the
model as an independent variable did not correlate with the
circadian BP pattern.
Discussion
A nocturnal fall in BP of less than 10% is the cutoff point
usually used in hypertensive patients to identify non-dippers [6,
131. This cutoff point is not relevant in our population: only
5 patients showed a nocturnal BP decrease higher than 10%, and
24 patients (57%) had an absent or an inversed nycthemeral BP
pattern. These results emphasize the high prevalence of nycthem-
eral BP rhythm impairment in treated hypertensive patients on
hemodialysis, and suggest the lack of efficacy of antihypertensive
drugs to restore the circadian BP pattern. No significant difference
in LVH was observed between dippers and non-dippers. This lack
of difference could be related to an inadequate population size.
However, the role of nycthemeral BP pattern on LVH is still
debated. In a recent metaanalysis Fagard, Staessen and Thijs [141
were unable to demonstrate influence of ambulatory BP pressure
Table 4. Relationships between pulse wave velocity, age, casual and
ambulatory blood pressure. Statistical analysis using Pearson correlation
coefficients (BP: Blood pressure)
r P
Age 0.37 0.01
Casual BP
Systolic 0.47 0.001
Diastolic 0.37 0.01
24-Hour ambulatory BP
Systolic 0.43 0.003
Diastolic 0.13 0.39
Diurnal ambulatory BP
Systolic 0.28 0.06
Diastolic 0.06 0.7
Nocturnal ambulatory BP
Systolic 0.36 0.01
Diastolic 0.08 0.59
Heart rate variability (standard deviation)
24-hour heart rate variability 0.04 0.79
Diurnal heart rate variability 0.03 0.82
Nocturnal heart rate variability 0.02 0.85
profile on left ventricular mass. In our study, no significant
difference in interdialytic weight gain according to the nycthem-
eral BP pattern was observed. This result is in agreement with the
data reported by Luik et al [15] on the effect of fluid changes on
day-night ambulatory BP differences, and suggests that volume
overload is not relevant in the blunted day-night differences
recorded in hemodialysis patients. Erythropoietin therapy and
pulse wave velocity are independently correlated to nycthemeral
BP pattern impairment. The pressor effect of eiythropoietin has
been already established, and is probably related to the expansion
of red cell volume leading to an increase in vascular resistances via
an increase in blood viscosity [16—18]. Hemoglobin binds nitric
oxyde and may therefore inhibit the action of this endogenous
vasodilator [19]. A deleterious influence of EPO therapy on
ambulatory BP profile has been previously reported [20, 21]. As
the hemoglobin levels were similar in the two groups of patients,
and the mean dose of EPO was not significantly different between
dippers and non-dippers, it is not possible to assert this deleteri-
ous influence in our study group. Moreover, we cannot determine
whether it is the influence of EPO or the hemodynamic alterations
related to more severe anemia requiring epogen therapy that lead
to a blunted BP pattern, in the absence of prospective results. Our
results show that arterial stiffness evaluated by PWV and the lack
of fall in nocturnal BP are linked independently of age and BP.
This relationship has been previously established in essential
hypertensive patients with an elevated waist:hip ratio [22]. From a
pathophysiological point of view, the lack of fall in nocturnal BP
leads to an increase in arterial wall stress and contributes to
vascular remodeling and intima media thickening [23]. Hence, an
impaired nycthemeral rhythm could favor arterial stiffness. Our
data support this hypothesis. Indeed, we found a positive relation-
ship between PWV and 24-hour ambulatory systolic BP. On the
other hand, Kool et a! [24] demonstrated that the nocturnal BP
fall correlates to an increase in carotid diameter and a decrease in
pulse pressure. A decline in arterial distensibility could modify
this mechanism and contribute to alter the nycthemeral BP
rhythm. In the non-dippers group, we found a higher level of
intact PTH than in dippers. It has been shown that hyperparathy-
roidism occurs both with an increase of Ca2 and hypertension
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[251. Moreover, Amann et a! have demonstrated that PTH has a
permissive effect on arterial wall hypertrophy in experimental
uremia [261. In addition, our results suggest a link between
nycthemeral BP pattern and intact PTH. However, the lack of
correlation observed in our study between PTH and PWV does
not argue for the confounding role of aortic stiffness on the link
between intact PTH and blunted nycthemeral BP pattern.
Inversely to PWV, we did not find any correlation between PP
and circadian BP pattern. However, PP is not only determined by
arterial stiffness but also by ventricular ejection time and the
timing of the reflect wave [27—30]. These parameters could explain
the lack of correlation between PP and ambulatoiy blood pressure
profile in our study group. Further studies are needed to support
these hypothesis.
In summary, our results show that arterial distensibility and
nycthemeral BP profile are linked in ESRD, and these cardiovas-
cular risk factors should both be taken into account in the
management of hypertensive hemodialysis patients. Our study
emphazises the interest of ABPM to identify hypertensive hemo-
dialysis patients at high vascular risk.
Reprint requests to Dr. I. Vernier, Service de Nephroiogie et d'Hémodialyse,
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